Nanobiotechnology Laboratory, Biology Department, Faculty of Science, Razi University, Kermanshah, Iran.
Regional Centre of Advanced Technologies and Materials, Palacky University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic.
Int J Biol Macromol. 2020 Dec 1;164:2197-2203. doi: 10.1016/j.ijbiomac.2020.07.274. Epub 2020 Aug 5.
Severe side effects and the rapid emergence of drug resistance in cancer cells are major problems in the chemotherapy utilizing anthracyclines, with a difference between cellular response at nano and micro scale levels. Understanding this situation is more complicated issue to attain efficient targeted formulations with low unexpected toxicity in patients. On nano-scale level, considering properties of nano-bio interaction in all relevant parts of the body may offer clue for suitable formulations. Four main strategies comprising PEGylation, surface charging, targeting, and stimuli responsiveness can be deployed to improve the liposomal and polymeric nanoformulations that can efficiently deliver common anthracyclines namely daunorubicin (DAU), doxorubicin (DOX), idarubicin (IDA), and epirubicin (EPI). Herein, the advances and challenges pertaining to the formulations of these anticancer drugs via liposomal and polymeric nanoformulations, are discussed.
在利用蒽环类药物进行化疗时，癌细胞会产生严重的副作用和快速耐药性，这是一个主要问题。在纳米和微米尺度上，细胞反应存在差异。了解这种情况对于获得具有低意外毒性的高效靶向制剂是一个更加复杂的问题。在纳米尺度上，考虑纳米生物相互作用在体内所有相关部位的特性，可能为合适的制剂提供线索。可以采用四种主要策略来改进脂质体和聚合物纳米制剂，即聚乙二醇化、表面电荷、靶向和刺激响应性，以有效地递送常见的蒽环类药物，即柔红霉素（DAU）、多柔比星（DOX）、伊达比星（IDA）和表柔比星（EPI）。本文讨论了通过脂质体和聚合物纳米制剂来制备这些抗癌药物的进展和挑战。
